NCT05488405

Mesalazine Oral Suspension in Active Eosinophilic Esophagitis

Open-label, Monocentric Phase IIa Pilot Study Evaluating the Efficacy and Tolerability of a 4-week Treatment With Mesalazine Oral Suspension in Patients With Active Eosinophilic Esophagitis

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 5 (actual)
• Sponsor: Dr. Falk Pharma GmbH · Industry
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

Pilot study to assess a mesalazine oral suspension in active eosinophilic esophagitis

Detailed description

This is an open-label, monocentric exploratory phase IIa pilot study, which serves to evaluate the efficacy, safety, and tolerability of treatment with mesalazine oral suspension for the treatment of active eosinophilic esophagitis (EoE).

Conditions

• Eosinophilic Esophagitis

Interventions

Type	Name	Description
DRUG	Mesalamine Oral Product	Mesalamine oral suspension for oral use

Timeline

• Start date: 2023-02-09
• Primary completion: 2023-06-30
• Completion: 2023-07-20
• First posted: 2022-08-04
• Last updated: 2023-09-07

Locations

1 site across 1 country: Switzerland